Greenwich LifeSciences, Inc. (Nasdaq: $GLSI) presented open-label data from the FLAMINGO-01 Phase III trial of GLSI-100 at the 2026 AACR Meeting. In the non-HLA-A*02 arm (n=247), treatment led to a statistically significant ~4x increase in DTH immune reactions (from 5.2% at baseline to 20.4% at month 4/6, p<0.001), with immune reactivity rising across HLA-A types and a preliminary ~70-80% reduction in recurrence rate after the primary immunization series. @GreenwichLS Link: globenewswire.com/news-relea… #BreastCancerVaccine #Phase3Data #Immunotherapy #AACR2026

🚀 BLTE (Belite Bio): Biotech Rocket on Phase 3 Breakthrough – Stargardt Drug Hits Primary Endpoint 📈BLTE is spiking on bullish drug data today. Trend is strong and at the fifty‑two‑week high. News says Phase 3 for Stargardt hit topline. Tape shows heavy move and strong momentum. Size small. Use limit orders. Belite Bio $BLTE, a clinical-stage biopharma focused on retinal degenerative diseases, exploded 17% pre-market to ~$144 on December 1, 2025, after announcing positive topline results from the global Phase 3 DRAGON trial for Tinlarebant in adolescents with Stargardt disease (STGD1)—the first pivotal success for this untreatable condition affecting 1 in 8,000-10,000 people. The trial met its primary endpoint with a statistically significant 36% reduction in retinal lesion growth rate vs. placebo (p<0.001), plus favorable safety (no serious adverse events), paving the way for regulatory filings in H1 2026—Cantor Fitzgerald initiated Overweight with $154 PT ( 7%), Mizuho Hold at $80, but consensus Strong Buy from 6 analysts at $113.8 avg PT (-17% from $137 close, but outdated pre-news). Market cap ~$3.3B, no revenue yet (Q3 net loss $21.7M on R&D ramp), but $300M cash runway through 2027 supports Tinlarebant commercialization; shares up 376% YTD on pipeline (Tinlarebant also in dry AMD Phase 2), with Zacks no Rank yet but Seeking Alpha Strong Buy on undervaluation, TipRanks sentiment positive, VectorVest growth signal; high volume 5M avg signals momentum—projected 40% to $190 on approvals, but probe risks and biotech vol loom. BLTE's Momentum Edge: Breakthrough data de-risks NDA (FDA/EU priority review likely), unlocking $1B peak sales in rare disease; overlaps with Qullamaggie EP breakout (3% run above $130), A Setups flag on higher lows, Morningstar B-grade on innovation—watch $150 resistance for squeeze. Thoughts on BLTE's Phase 3 moonshot—adding on the pop or waiting for pullback? Reply with your thesis, repost if it's on your radar, and follow for more biotech catalysts. #BLTE #BiotechBreakthrough #StargardtDisease #Tinlarebant #Phase3Data #RareDisease #StockMomentum #FDAWatch Follow @BangerDayTrades for daily ST/LT bangers. The Sky is the Limit 💎 (NOT FINANCIAL ADVICE)

Excellent Presentation Slides: Immunization With Autologous Dendritic Cells is Associated With Extended Survival in Glioblastoma Patients, By Marnix Bosch, March 15, 2023 $NWBO #DCVaxL #Phase3Data nwbio.com/wp-content/uploads…

Presentation Webinar: Dr. Linda Liau talks about the results of her Phase 3 trial of DcVax for Newly Diagnosed and Recurrent Glioblastoma youtu.be/jhtDz-Hhsbg via @YouTube #DCVaxL #DCVax #DrLindaLiau $NWBO #Phase3TLD #Phase3Data #Glioblastoma #CancerVaccine #FinalPhase3

Webinar: Dr. Linda Liau talks about the results of her Phase 3 trial of DcVax youtu.be/jhtDz-Hhsbg via @YouTube #DCVaxL #DCVax #DrLindaLiau $NWBO #Phase3TLD #Phase3Data #Glioblastoma #CancerVaccine See the JAMA Oncology below this tweet

Webinar: Dr. Linda Liau talks about the results of her Phase 3 trial of DcVax youtu.be/jhtDz-Hhsbg via @YouTube #DCVaxL #DCVax #DrLindaLiau $NWBO #Phase3TLD #Phase3Data #Glioblastoma #CancerVaccine See the JAMA Oncology tinyurl.com/DCVaxLJAMA

$NWBO #DCVaxL #Phase3Data

Bharat Biotech has submitted Phase 3 data on Covaxin trials: Health official #BharatBiotech #Covaxin #Phase3Data thenewsminute.com/article/bh…

So Bharat Biotech guys are like: hum kaagaz nahin dikhayenge? Bhai galat jagah pe galat nara! #Covaxin #phase3data

Will the real Ella please stand up?#phase3data #covaxin

Dr. Lindborg, VP @BCLI said today: "Therefore, we reached the conclusion which we’ve shared repeatedly, even today, that we believe strongly in the efficacy of NurOwn". Yeah, ya think? #ALS #ALSA #ENDALS #PHASE3DATA

Ei vielä. @SCMPNews kertoi asiasta hetki sitten. Julkaisevat kaiken tarpeellisen #Phase3Data 1-2 viikon sisällä. Ilmeisesti testit ovat siten menneet hyvin. 😊 Kun #Pfizervaccine juuri ilmoitti joutuvansa puolittamaan tuotantonsa 2020 (➡️50M), niin Kiinan 600M on huippuluku.

Northwest Biotherapeutics: Reason for Yesterday's Stock Surge ( $NWBO, Buy, $1.12) | Expert Financial Analysis and Reporting | Smith on Stocks #CancerVaccine #Phase3Data coming shortly. smithonstocks.com/northwest-…

$NWBO #DCVaxL #Phase3Data Data Lock is pending, with more info in the 10Q. From 5-24-20 10Q “Overview” section: “Accordingly, the Company is aiming to proceed with data lock at approximately the end of next week.” sec.gov/Archives/edgar/data/…

let's do this! #bremelanotide #hsdd #palatin $PTN #onetime #sexsells #phase3data #phase3 #buyout #addyikiller